Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model

Thrombosis and Haemostasis

Volumn 80, Issue 1, 1998, Pages 186-191

  Deschênes, Isabelle ^a   Finkle, Carolyn D ^a   Winocour, Peter D ^a  

^a Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO PHENYLALANYLPROLYL 5 AMINOVALERYL 5 AMINOVALERYLASPARTYLPHENYLALANYLGLUTAMYLPROLYLISOLEUCYLPROLYLLEUCINE; HEPARIN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CAROTID ARTERY; CONTROLLED STUDY; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT;

EID: 2642675221     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615161     Document Type: Article

References (52)

1. Becker RC. Seminars in thrombosis, thrombolysis and vascular biology (4. fibrinolysis). Cardiology 1991; 79: 188-210.
2. Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator a review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346-88.
3. Sobel BE. Thrombolysis in the Treatment of Acute Myocardial Infarction. In: Thrombosis in Cardiovascular Disorders. Fuster V, Verstraete M, eds. Saunders, Philadelphia, PA 1992: pp. 289-326.
4. Kleiman NS. Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Coronary Artery Disease 1996; 7: 508-15.
5. Weitz JI, Hirsh J. Antithrombins: their potential as antithrombotic agents. Annu Rev Med 1992; 43: 9-16.
6. Weitz JI. New anticoagulant strategies current status and future potential. Drugs 1994; 48: 485-97.
7. Weitz JI, Clikk RM, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. Chest 1995; 108: 471S-85S.
8. Kéréveur A, Samama MM. New antithrombotic agents. La Presse Médicale 1995; 24: 1777-87.
9. Freek WA, Verheugt AM, Lagrand VK, van Eenige MJ. Reocclusion: the flip side of coronary thrombolysis. J Am Coll Cardiol 1996; 27: 766-73.
10. Chesebro JH, Knatterud G, Robert R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hills D Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J. Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54.
11. TIMI Study Group. The thrombolysis in myocardial infarction trial: phase I findings. N Engl J Med 1985; 312: 932-6.
12. Meijer A, Verheugt FW, Werter CJPJ, Lie KI, Van Der Pol JM, Van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographie study. Results of the APRICOT study. Circulation 1993; 87: 1524-30.
13. Sobel BE. Coronary thrombolysis and the new biology. J Am Coll Cardiol 1989; 14: 850-60.
14. Collen D, Topol EJ, Tiefenbrunn AJ. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-17.
15. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
16. Fenton JW, Ni F, Witting JI, Brezniak DV, Anderson TT, Malik AB. The Rational Design of Thrombin-Directed Antithrombotics. In: The Design of Synthetic Inhibitors of Thrombin. Claeson G, et al. eds. Plenum Press, New York, NY 1993: pp. 1-11
17. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coronary Artery Disease 1997; 8: 105-11.
18. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis. Circulation 1997; 96: 2118-20.
19. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-56.
20. Martin U, Dörge L, Fisher S. Comparison of desulfatohirudin (REVASC) and heparin as adjunct to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Br J Pharmacol 1996; 118: 271-6.
21. Rübsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin. Thromb Haemost 1996; 76: 105-10.
22. Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circulation Research 1993; 72: 1091-102.
23. Maraganore JM. Hirudin and hirulog: advances in antithrombotic therapy. Perspectives in drug discovery and design 1993; 1: 461-78.
24. Mattsson C, Björkman JA, Ulvinge JC. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis & Proteolysis 1997; 11: 121-8.
25. Rübsamen K, Eschenfelder V. Effect of recombinant hirudin (LU52369) on reocclusion rates after thrombolysis in rabbits. Haemostasis 1991; 21 (suppl 1):93-8.
26. Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost 1990; 63: 44-7.
27. Agnelli G, Pascucci C, Cosmi B, Nenci G. Effects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits. Thromb Haemost 1991; 66: 592-7.
28. Agnelli G, Pascucci C, Cosmi B, Nenci G. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-6.
29. Lenfors S, Marberg L, Wikström S, Jonsson U, Eriksson AW, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coagulation and Fibrinolysis 1993; 4: 263-71.
30. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-8.
31. Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effect of recombinant hirudin, heparin, or aspirin. Circulation 199; 93: 792-9.
32. Markwardt F. The development of hirudin as an antithrombotic drug Thromb Res 1994; 74: 1-23.
33. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochem 1990; 29: 7095-107.
34. Cannon CP, McCabe CH, Henry TD. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
35. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-2: a factorial randomised trial of alteplase vs streptokinase and heparin versus no heparin among 12,490 patients with acute myocardia infarction. Lancet 1990; 336: 65-71.
36. ISIS-3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
37. Théroux P, Perez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-8.
38. White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B, on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155-61.
39. Antmann EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
40. Global Use of Strategies to Open Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
41. Neuhaus KL, con Essen R, Tebbe U. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft leitender kardiologischer Krankenhausartze (ALKK). Circulation 1994; 90: 1638-42.
42. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. New Engl J Med 1996; 335: 775-81.
43. Antmann EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94 (5): 911-21.
44. Fitzgerald GA. The human pharmacology of thrombin inhibition. Coronary Artery Disease 1996; 7: 911-8.
45. Finkle CD, St. Pierre A, Leblond L, Deschênes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis; comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998; 79: 431-8.
46. DiMaio J, Ni F, Gibbs B, Konishi Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bound. FEBS 1991; 282: 47-52.
47. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res11 1990; 60: 269-80.
48. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
49. Jang I-K, Gold HK, Kiskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 920-8.
50. Yao S-K, McNatt J, Anderson HV, Eidt J, Cui K, Golino P, Glas-Greenwaltz P, Maraganore J, Buja LM, Willerson JT. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am Physiological Society 1992; H374-9.
51. Voytik S, Badylak F, Burke S, Klabunde RE, Henkm J. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis. Thromb Haemost 1990; 64: 438-44.
52. Weitz JI, Hudoba M, Massel D, Maraganore JM, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombm III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.